Annual EBITDA
-$11.23 M
-$6.32 M-128.62%
December 31, 2023
Summary
- As of February 10, 2025, ANIK annual EBITDA is -$11.23 million, with the most recent change of -$6.32 million (-128.62%) on December 31, 2023.
- During the last 3 years, ANIK annual EBITDA has fallen by -$10.23 million (-1018.73%).
- ANIK annual EBITDA is now -116.98% below its all-time high of $66.15 million, reached on December 31, 2014.
Performance
ANIK EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
-$22.73 M
-$24.95 M-1124.25%
September 30, 2024
Summary
- As of February 10, 2025, ANIK quarterly EBITDA is -$22.73 million, with the most recent change of -$24.95 million (-1124.25%) on September 30, 2024.
- Over the past year, ANIK quarterly EBITDA has dropped by -$18.60 million (-450.05%).
- ANIK quarterly EBITDA is now -190.66% below its all-time high of $25.07 million, reached on March 31, 2014.
Performance
ANIK Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
-$21.53 M
-$18.60 M-634.68%
September 30, 2024
Summary
- As of February 10, 2025, ANIK TTM EBITDA is -$21.53 million, with the most recent change of -$18.60 million (-634.68%) on September 30, 2024.
- Over the past year, ANIK TTM EBITDA has dropped by -$5.31 million (-32.75%).
- ANIK TTM EBITDA is now -132.54% below its all-time high of $66.15 million, reached on December 31, 2014.
Performance
ANIK TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
ANIK EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -128.6% | -450.1% | -32.8% |
| 3 y3 years | -1018.7% | -1693.8% | -896.1% |
| 5 y5 years | -140.6% | -267.6% | -153.5% |
ANIK EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -169.8% | at low | -1124.3% | at low | -682.5% | at low |
| 5 y | 5-year | -127.9% | at low | -458.8% | at low | -153.5% | at low |
| alltime | all time | -117.0% | at low | -190.7% | at low | -132.5% | at low |
Anika Therapeutics EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$22.73 M(-1124.2%) | -$21.53 M(+634.7%) |
| Jun 2024 | - | $2.22 M(-174.0%) | -$2.93 M(-44.0%) |
| Mar 2024 | - | -$3.00 M(-251.3%) | -$5.23 M(-53.4%) |
| Dec 2023 | -$11.23 M(+128.6%) | $1.98 M(-148.0%) | -$11.23 M(-30.7%) |
| Sep 2023 | - | -$4.13 M(+5001.2%) | -$16.22 M(+12.7%) |
| Jun 2023 | - | -$81.00 K(-99.1%) | -$14.39 M(+2.9%) |
| Mar 2023 | - | -$9.00 M(+200.0%) | -$13.98 M(+184.5%) |
| Dec 2022 | -$4.91 M(+18.0%) | -$3.00 M(+30.3%) | -$4.91 M(-24.2%) |
| Sep 2022 | - | -$2.30 M(-802.1%) | -$6.48 M(+135.6%) |
| Jun 2022 | - | $328.00 K(+420.6%) | -$2.75 M(-32.0%) |
| Mar 2022 | - | $63.00 K(-101.4%) | -$4.05 M(-2.8%) |
| Dec 2021 | -$4.16 M(+314.6%) | -$4.57 M(-420.3%) | -$4.16 M(+92.6%) |
| Sep 2021 | - | $1.43 M(-247.5%) | -$2.16 M(-44.0%) |
| Jun 2021 | - | -$967.00 K(+1690.7%) | -$3.86 M(-14.9%) |
| Mar 2021 | - | -$54.00 K(-97.9%) | -$4.54 M(+351.7%) |
| Dec 2020 | -$1.00 M(-102.5%) | -$2.57 M(+839.9%) | -$1.00 M(-112.7%) |
| Sep 2020 | - | -$273.00 K(-83.4%) | $7.90 M(-63.7%) |
| Jun 2020 | - | -$1.64 M(-147.2%) | $21.73 M(-40.9%) |
| Mar 2020 | - | $3.48 M(-45.1%) | $36.76 M(-8.7%) |
| Dec 2019 | $40.24 M(+45.5%) | $6.33 M(-53.3%) | $40.24 M(-10.9%) |
| Sep 2019 | - | $13.56 M(+1.4%) | $45.14 M(+8.3%) |
| Jun 2019 | - | $13.38 M(+92.3%) | $41.66 M(+1.7%) |
| Mar 2019 | - | $6.96 M(-38.1%) | $40.98 M(+48.2%) |
| Dec 2018 | $27.66 M(-44.7%) | $11.24 M(+11.4%) | $27.66 M(+1.6%) |
| Sep 2018 | - | $10.09 M(-20.5%) | $27.21 M(-4.8%) |
| Jun 2018 | - | $12.69 M(-299.6%) | $28.60 M(-17.4%) |
| Mar 2018 | - | -$6.36 M(-158.9%) | $34.64 M(-30.7%) |
| Dec 2017 | $50.02 M(-8.0%) | $10.79 M(-5.9%) | $50.02 M(-5.5%) |
| Sep 2017 | - | $11.47 M(-38.8%) | $52.92 M(-5.5%) |
| Jun 2017 | - | $18.73 M(+107.7%) | $56.02 M(+8.3%) |
| Mar 2017 | - | $9.02 M(-34.1%) | $51.71 M(-4.8%) |
| Dec 2016 | $54.34 M(+4.7%) | $13.70 M(-6.0%) | $54.34 M(-7.4%) |
| Sep 2016 | - | $14.56 M(+0.9%) | $58.69 M(+0.8%) |
| Jun 2016 | - | $14.43 M(+23.8%) | $58.23 M(+1.9%) |
| Mar 2016 | - | $11.65 M(-35.4%) | $57.14 M(+10.1%) |
| Dec 2015 | $51.91 M(-21.5%) | $18.04 M(+27.9%) | $51.91 M(+10.2%) |
| Sep 2015 | - | $14.11 M(+5.7%) | $47.09 M(+5.9%) |
| Jun 2015 | - | $13.34 M(+107.9%) | $44.47 M(-6.4%) |
| Mar 2015 | - | $6.42 M(-51.4%) | $47.50 M(-28.2%) |
| Dec 2014 | $66.15 M(+78.3%) | $13.22 M(+15.0%) | $66.15 M(+2.2%) |
| Sep 2014 | - | $11.50 M(-29.8%) | $64.72 M(+4.2%) |
| Jun 2014 | - | $16.37 M(-34.7%) | $62.10 M(+10.7%) |
| Mar 2014 | - | $25.07 M(+112.8%) | $56.08 M(+51.2%) |
| Dec 2013 | $37.09 M(+38.5%) | $11.78 M(+32.7%) | $37.09 M(+0.8%) |
| Sep 2013 | - | $8.88 M(-14.3%) | $36.80 M(+15.6%) |
| Jun 2013 | - | $10.36 M(+70.4%) | $31.83 M(+10.5%) |
| Mar 2013 | - | $6.08 M(-47.1%) | $28.81 M(+7.6%) |
| Dec 2012 | $26.78 M(+49.0%) | $11.49 M(+193.9%) | $26.78 M(+25.9%) |
| Sep 2012 | - | $3.91 M(-46.7%) | $21.26 M(-8.2%) |
| Jun 2012 | - | $7.33 M(+81.0%) | $23.17 M(+12.8%) |
| Mar 2012 | - | $4.05 M(-32.2%) | $20.54 M(+14.3%) |
| Dec 2011 | $17.97 M(+65.5%) | $5.97 M(+2.7%) | $17.97 M(+17.2%) |
| Sep 2011 | - | $5.82 M(+23.9%) | $15.34 M(+23.8%) |
| Jun 2011 | - | $4.70 M(+218.1%) | $12.39 M(+20.2%) |
| Mar 2011 | - | $1.48 M(-55.8%) | $10.31 M(-5.1%) |
| Dec 2010 | $10.86 M(+57.8%) | $3.34 M(+16.4%) | $10.86 M(+15.3%) |
| Sep 2010 | - | $2.87 M(+9.9%) | $9.41 M(+5.9%) |
| Jun 2010 | - | $2.61 M(+28.9%) | $8.89 M(+13.7%) |
| Mar 2010 | - | $2.03 M(+6.8%) | $7.82 M(+13.6%) |
| Dec 2009 | $6.88 M(+21.6%) | $1.90 M(-19.0%) | $6.88 M(+4.6%) |
| Sep 2009 | - | $2.35 M(+52.0%) | $6.58 M(+11.4%) |
| Jun 2009 | - | $1.54 M(+41.2%) | $5.91 M(+4.9%) |
| Mar 2009 | - | $1.09 M(-31.7%) | $5.63 M(-0.5%) |
| Dec 2008 | $5.66 M | $1.60 M(-4.3%) | $5.66 M(-12.1%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2008 | - | $1.67 M(+32.1%) | $6.44 M(-5.8%) |
| Jun 2008 | - | $1.27 M(+12.7%) | $6.84 M(-4.0%) |
| Mar 2008 | - | $1.12 M(-52.8%) | $7.12 M(-3.5%) |
| Dec 2007 | $7.38 M(+27.0%) | $2.38 M(+14.9%) | $7.38 M(+23.8%) |
| Sep 2007 | - | $2.07 M(+33.5%) | $5.96 M(+4.6%) |
| Jun 2007 | - | $1.55 M(+11.9%) | $5.70 M(-6.0%) |
| Mar 2007 | - | $1.38 M(+44.1%) | $6.07 M(+4.4%) |
| Dec 2006 | $5.81 M(-35.5%) | $960.80 K(-46.8%) | $5.81 M(-0.2%) |
| Sep 2006 | - | $1.81 M(-5.7%) | $5.82 M(-27.7%) |
| Jun 2006 | - | $1.92 M(+70.2%) | $8.06 M(-2.0%) |
| Mar 2006 | - | $1.13 M(+15.7%) | $8.22 M(-8.8%) |
| Dec 2005 | $9.01 M(+27.0%) | $973.80 K(-75.9%) | $9.01 M(-15.1%) |
| Sep 2005 | - | $4.04 M(+94.2%) | $10.61 M(+28.4%) |
| Jun 2005 | - | $2.08 M(+8.6%) | $8.26 M(+8.1%) |
| Mar 2005 | - | $1.92 M(-25.6%) | $7.64 M(+7.7%) |
| Dec 2004 | $7.10 M(+343.3%) | $2.57 M(+52.2%) | $7.10 M(+26.4%) |
| Sep 2004 | - | $1.69 M(+15.9%) | $5.61 M(+23.0%) |
| Jun 2004 | - | $1.46 M(+6.6%) | $4.57 M(+41.2%) |
| Mar 2004 | - | $1.37 M(+25.5%) | $3.23 M(+101.9%) |
| Dec 2003 | $1.60 M(-173.5%) | $1.09 M(+69.8%) | $1.60 M(+2.3%) |
| Sep 2003 | - | $643.00 K(+406.3%) | $1.56 M(+582.2%) |
| Jun 2003 | - | $127.00 K(-148.7%) | $229.40 K(-127.2%) |
| Mar 2003 | - | -$261.00 K(-124.7%) | -$844.80 K(-61.2%) |
| Dec 2002 | -$2.18 M(-64.7%) | $1.06 M(-252.5%) | -$2.18 M(-37.4%) |
| Sep 2002 | - | -$692.60 K(-26.9%) | -$3.48 M(-10.1%) |
| Jun 2002 | - | -$947.20 K(-40.6%) | -$3.87 M(-29.3%) |
| Mar 2002 | - | -$1.60 M(+553.8%) | -$5.48 M(-7.9%) |
| Dec 2001 | -$6.18 M(-2981.0%) | -$244.10 K(-77.5%) | -$5.95 M(+78.8%) |
| Sep 2001 | - | -$1.08 M(-57.6%) | -$3.33 M(-9.4%) |
| Jun 2001 | - | -$2.56 M(+23.5%) | -$3.67 M(+180.1%) |
| Mar 2001 | - | -$2.07 M(-186.9%) | -$1.31 M(-684.8%) |
| Dec 2000 | $214.40 K(-80.5%) | $2.38 M(-266.4%) | $224.30 K(-112.1%) |
| Sep 2000 | - | -$1.43 M(+641.9%) | -$1.86 M(+334.3%) |
| Jun 2000 | - | -$192.70 K(-63.8%) | -$427.70 K(>+9900.0%) |
| Mar 2000 | - | -$533.00 K(-278.9%) | -$1700.00(-100.2%) |
| Dec 1999 | $1.10 M(-67.5%) | $298.00 K(>+9900.0%) | $966.90 K(+14.8%) |
| Sep 1999 | - | $0.00(-100.0%) | $842.20 K(-41.6%) |
| Jun 1999 | - | $233.30 K(-46.4%) | $1.44 M(-56.4%) |
| Mar 1999 | - | $435.60 K(+151.4%) | $3.31 M(-4.7%) |
| Dec 1998 | $3.37 M(-3.6%) | $173.30 K(-71.1%) | $3.47 M(-45.7%) |
| Sep 1998 | - | $600.00 K(-71.4%) | $6.40 M(+14.3%) |
| Jun 1998 | - | $2.10 M(+250.0%) | $5.60 M(+40.0%) |
| Mar 1998 | - | $600.00 K(-80.6%) | $4.00 M(+8.1%) |
| Dec 1997 | $3.50 M(-266.7%) | $3.10 M(-1650.0%) | $3.70 M(-1950.0%) |
| Sep 1997 | - | -$200.00 K(-140.0%) | -$200.00 K(-60.0%) |
| Jun 1997 | - | $500.00 K(+66.7%) | -$500.00 K(-68.8%) |
| Mar 1997 | - | $300.00 K(-137.5%) | -$1.60 M(-44.8%) |
| Dec 1996 | -$2.10 M(-8.7%) | - | - |
| Nov 1996 | - | -$800.00 K(+60.0%) | -$2.90 M(+16.0%) |
| Aug 1996 | - | -$500.00 K(-16.7%) | -$2.50 M(-10.7%) |
| Aug 1996 | -$2.30 M(+43.8%) | - | - |
| May 1996 | - | -$600.00 K(-40.0%) | -$2.80 M(+7.7%) |
| Feb 1996 | - | -$1.00 M(+150.0%) | -$2.60 M(+52.9%) |
| Nov 1995 | - | -$400.00 K(-50.0%) | -$1.70 M(0.0%) |
| Aug 1995 | -$1.60 M(+33.3%) | -$800.00 K(+100.0%) | -$1.70 M(+30.8%) |
| May 1995 | - | -$400.00 K(+300.0%) | -$1.30 M(-7.1%) |
| Feb 1995 | - | -$100.00 K(-75.0%) | -$1.40 M(-6.7%) |
| Nov 1994 | - | -$400.00 K(0.0%) | -$1.50 M(+25.0%) |
| Aug 1994 | -$1.20 M(-25.0%) | -$400.00 K(-20.0%) | -$1.20 M(-7.7%) |
| May 1994 | - | -$500.00 K(+150.0%) | -$1.30 M(+8.3%) |
| Feb 1994 | - | -$200.00 K(+100.0%) | -$1.20 M(+20.0%) |
| Nov 1993 | - | -$100.00 K(-80.0%) | -$1.00 M(+11.1%) |
| Aug 1993 | -$1.60 M | -$500.00 K(+25.0%) | -$900.00 K(+125.0%) |
| May 1993 | - | -$400.00 K | -$400.00 K |
FAQ
- What is Anika Therapeutics annual EBITDA?
- What is the all time high annual EBITDA for Anika Therapeutics?
- What is Anika Therapeutics annual EBITDA year-on-year change?
- What is Anika Therapeutics quarterly EBITDA?
- What is the all time high quarterly EBITDA for Anika Therapeutics?
- What is Anika Therapeutics quarterly EBITDA year-on-year change?
- What is Anika Therapeutics TTM EBITDA?
- What is the all time high TTM EBITDA for Anika Therapeutics?
- What is Anika Therapeutics TTM EBITDA year-on-year change?
What is Anika Therapeutics annual EBITDA?
The current annual EBITDA of ANIK is -$11.23 M
What is the all time high annual EBITDA for Anika Therapeutics?
Anika Therapeutics all-time high annual EBITDA is $66.15 M
What is Anika Therapeutics annual EBITDA year-on-year change?
Over the past year, ANIK annual EBITDA has changed by -$6.32 M (-128.62%)
What is Anika Therapeutics quarterly EBITDA?
The current quarterly EBITDA of ANIK is -$22.73 M
What is the all time high quarterly EBITDA for Anika Therapeutics?
Anika Therapeutics all-time high quarterly EBITDA is $25.07 M
What is Anika Therapeutics quarterly EBITDA year-on-year change?
Over the past year, ANIK quarterly EBITDA has changed by -$18.60 M (-450.05%)
What is Anika Therapeutics TTM EBITDA?
The current TTM EBITDA of ANIK is -$21.53 M
What is the all time high TTM EBITDA for Anika Therapeutics?
Anika Therapeutics all-time high TTM EBITDA is $66.15 M
What is Anika Therapeutics TTM EBITDA year-on-year change?
Over the past year, ANIK TTM EBITDA has changed by -$5.31 M (-32.75%)